Trails of discovery: The discovery of the fibrates

Dialogues in Cardiovascular Medicine

Volumn 8, Issue 3, 2003, Pages 155-162

  Fitzgerald, Desmond ^a  

^a Materia Medica   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTERONE; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER; CIPROFIBRATE; CLOBUZARIT; CLOFIBRATE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; METHYLCLOFENAPATE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLACETIC ACID; PHOSPHOLIPID; THYROID HORMONE; TRIACYLGLYCEROL;

ARTICLE; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; GLYCEROL BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; LIPOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0344445509     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature. 1962;194:948-949.
2. Thorp JM. An experimental approach to the problem of disordered lipid metabolism. J Atheroscler Res. 1963;3:351-360.
3. Horeau A, Jacques J. Structure moléculaire et activité œstrogène: acides hydroxynaphtypropioniques substitutés. C R Acad Sci. 1947;224:862-863.
4. Ridel J, Cottet J. Action hypocholestérolemiante de quelques acides acétiques disubstitutés. CR Soc Biol. 1953;237:441-442.
5. Cottet J et al. Pouvoir hypocholesterolémiant du phenyléthyl-acétate de sodium (22 TH) sur le rat. CR Soc Biol. 1953;237:441-442.
6. Galinberti T, Defranceschi A. Intesi di alcuni derivati α-isobutirici. Gaz Chim Ital. 1947;77:433-438.
7. Julia M, Baillarge M, Tchernoff G. Sur Quelques nouveaux dérivés aryloxyisobutyriques et apparentés. Bull Soc Chim France. 1956:776-783.
8. Thorp JM. Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxyisobutyrate. Lancet. 1962;1:1323-1326.
9. Symposium on atromid. Proceedings of a conference June 5th, 1963. J Atheroscler Res. 1963;3:347-753.
10. Fredrickson DS, Levy RI, Lees RS. Fat transport and lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med. 1967;276:34-42, 94-103, 148-156, 215-225, 273-281.
11. Hellman L, Zumoff B, Kessler G, et al. Reduction of serum cholesterol and lipids by ethyl chlorophenoxyisobutyrate. J Atheroscler Res. 1963;3:454-466.
12. Stone MC, Thorp JM, Wain JS. Experimental and clinical evaluation of the two "Atromid-S" analogues in relation to their differential modes of action. Adv Exp Biol Med. 1975;63:151-163.
13. Steinberg D. Drugs inhibiting cholesterol biosynthesis, with special reference to clofibrate. In: Jones RJ, ed. Atherosclerosis, Proceedings of Second International Symposium. 1970:500-508.
14. Reynolds PMG, McLeod MM, Dick WC. Clozic (ICI 55897) in rheumatoid arthritis. A controlled comparison with gold. Br J Clin Pract. 1981;35:306-312.
15. Billingham MEJ, Rushton AR. In: Rainsford KD, ed. Anti-inflammatory and anti-rheumatic drugs. London, UK: CRC Press; 1985:31-64.
16. Houlston R, Quiney J, Watts GF, Lewis B. Gemfibrozil in the treatment of resistant familial hypocholesterolaemia and Type III hyperlipoproteinaemia. J R Soc Med. 1988;81:274-276.
17. Gaw A, Packard CJ, Shepherd J. Fibrates. In: Schettler G, Habenicht JR, eds. Principles and Treatment of Lipoprotein Disorders. Berlin, Germany: Springer-Verlag; 1994:325-348.
18. Issemann I, Green S. Activation of a member of the steroid hormone receptor super family by peroxisome proliferators. Nature. 1990;347:645-650.
19. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83:841-850.
20. Bardo O, Aldrich TC, Latruffe N, Green S. PRAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the biofunctional enzyme gene. Biochem Biophys Res Commun. 1993;192:37-45.
21. Tucker MJ, Orton TC. Comparative Toxicology of Hypolipidaemic Fibrates. London, UK: Taylor & Francis; 1995:23-58.
22. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
23. Ashby J, Brady A, Elcombe CR, et al. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol. 1994;13(suppl 2):S1-S117.
24. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention Study. Circulation. 2000;102:21-27.
25. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol. 1998;32:1648-1656.
26. Brown PJ, Winetar DA, Plunket KD, et al. A ureido-thioisodutyric acid (GW 9578) is a sub-type selective PPAR a agonist with potent lipid lowering activity. J Med Chem. 1999;42:3785-3788.
27. Kuuabara K, Murakami K, Toto M, et al. A highly selective Peroxisome proliferator-activated receptor α (PRARα) agonist, NS220, decreases plasma glucose levels and ameliorates lipoprotein profiles in diabetic mice. Circulation. 2002;106(suppl II ):II210. Abstract 10.55.
28. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
29. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
30. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2-3.
31. Fujita T, Sugiyama Y, Taketomi S, et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63287, ciglitazone), a new antidiabetic agent. Diabetes. 1983;32:804-810.
32. Henke BR, Blanchard SG, Brackeen MF, et al. M-2-benzoylphenyl)-L-tyrosine PRAR gamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem. 1998;41:5020-5036.
33. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest. 2000:106:467-472.
34. Oliver WR, Shenk JL, Smith MR. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A. 2001;98: 5306-5311.
35. Miller RD. Atromid in the treatment of post-climactiric diabetes. J Atheroscler. 1963;3:694-700.
36. Kobayashi M, Shigeta Y, Hirata Y, et al. Improvement of glucose tolerance in NIDDM by clofibrates. Randomised double blind study. Diabetes Care. 1988;11:495-499.
37. Thorpe JM, Cotton RC, Oliver MF. Role of the endocrine system in the regulation of plasma lipids and fibrinogen with particular reference to the effects of "Atromid'S." In: Miras CJ, Howard AN, Paoletti R, eds. Progress in Biochemical Pharmacology. Basel, Switzerland: Karger; 1968;4:611-617.
38. Thorp JM, Horsfall GB, Stone MC. A new red sensitive micronephelometer [Technical note]. Med Bio Engin. 1967;5:51-56.
39. Thorp JM, Mills GL, Dick TBS. Diagnosis and classification of abnormal lipoprotein patterns. Clin Chim Acta. 1971;31:333-354.
40. Committee of Principal Investigators. A cooperative trial in the prevention of ischaemic heart disease using clofibrate. Br Heart J. 1978;40:1069-1118.
41. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol; mortality follow-up. Lancet. 1980;2:379-385.
42. Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984;2:600-604.
43. Oliver MF. Doubts about preventing coronary heart disease. BMJ. 1992;304:393-394.